{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:34:03Z","timestamp":1779143643503,"version":"3.51.4"},"reference-count":178,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.cgh.2013.01.005","type":"journal-article","created":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T11:45:10Z","timestamp":1357645510000},"page":"224-231.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Translating an Understanding of the Pathogenesis of Hepatic Fibrosis to Novel Therapies"],"prefix":"10.1016","volume":"11","author":[{"given":"Don C.","family":"Rockey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2013.01.005_bib1","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1083\/jcb.127.6.2037","article-title":"Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis","volume":"127","author":"Jarnagin","year":"1994","journal-title":"J Cell Biol"},{"key":"10.1016\/j.cgh.2013.01.005_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2008-1040452","article-title":"Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins","volume":"10","author":"Schuppan","year":"1990","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cgh.2013.01.005_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1089-3261(05)70113-6","article-title":"The cell and molecular biology of hepatic fibrogenesis","volume":"4","author":"Rockey","year":"2000","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2013.01.005_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1542-3565(04)00445-8","article-title":"Antifibrotic therapy in chronic liver disease","volume":"3","author":"Rockey","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_bib5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1172\/JCI1018","article-title":"Mechanisms of spontaneous resolution of rat liver fibrosis","volume":"102","author":"Iredale","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr1","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1172\/JCI118925","article-title":"Endothelin antagonism in experimental hepatic fibrosis","volume":"98","author":"Rockey","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr3","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.01.005_fr4","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr5","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jhep.2011.09.024","article-title":"Clinical evidence for the regression of liver fibrosis","volume":"56","author":"Ellis","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr6","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/hep.23528","article-title":"Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","article-title":"Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis","volume":"40","author":"Czaja","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr9","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJM200102083440604","article-title":"Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct","volume":"344","author":"Hammel","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr11","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.5858\/2000-124-1599-ROHC","article-title":"Regression of human cirrhosis","volume":"124","author":"Wanless","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7326\/0003-4819-127-11-199712010-00006","article-title":"Reversibility of hepatic fibrosis in autoimmune hepatitis","volume":"127","author":"Dufour","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cld.2006.08.017","article-title":"Hepatic fibrosis, stellate cells, and portal hypertension","volume":"10","author":"Rockey","year":"2006","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2013.01.005_fr14","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/hep.21792","article-title":"Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture","volume":"46","author":"Li","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jhep.2006.04.014","article-title":"Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis","volume":"45","author":"Kisseleva","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr16","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI200320530","article-title":"Epithelial-mesenchymal transition and its implications for fibrosis","volume":"112","author":"Kalluri","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr17","doi-asserted-by":"crossref","first-page":"22089","DOI":"10.1074\/jbc.M700998200","article-title":"Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro","volume":"282","author":"Kaimori","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cgh.2013.01.005_fr18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0074-7696(08)61977-4","article-title":"Perisinusoidal stellate cells (fat-storing cells, interstitial cells, lipocytes), their related structure in and around the liver sinusoids, and vitamin A-storing cells in extrahepatic organs","volume":"66","author":"Wake","year":"1980","journal-title":"Int Rev Cytol"},{"key":"10.1016\/j.cgh.2013.01.005_fr19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1096\/fasebj.5.3.2001786","article-title":"Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis","volume":"5","author":"Blomhoff","year":"1991","journal-title":"FASEB J"},{"key":"10.1016\/j.cgh.2013.01.005_fr20","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1172\/JCI114886","article-title":"Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo","volume":"86","author":"Maher","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr21","first-page":"193","article-title":"Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture","volume":"24","author":"Rockey","year":"1992","journal-title":"J Submicrosc Cytol Pathol"},{"key":"10.1016\/j.cgh.2013.01.005_fr22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejcb.2005.09.004","article-title":"Masters and servants of the force: the role of matrix adhesions in myofibroblast force perception and transmission","volume":"85","author":"Hinz","year":"2006","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.cgh.2013.01.005_fr23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/path.1427","article-title":"The myofibroblast in wound healing and fibrocontractive diseases","volume":"200","author":"Gabbiani","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.cgh.2013.01.005_fr24","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/hep.20965","article-title":"Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells","volume":"42","author":"Aleffi","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1042\/CS20110002","article-title":"Hepatic stellate cells stimulate HCC cell migration via laminin-5 production","volume":"121","author":"Santamato","year":"2011","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.cgh.2013.01.005_fr26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jhep.2012.06.012","article-title":"Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma","volume":"57","author":"Gentilini","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr27","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0016-5085(03)01194-6","article-title":"The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C","volume":"125","author":"Bonacchi","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.01.005_fr28","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1073\/pnas.92.7.2572","article-title":"Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions","volume":"92","author":"Sanderson","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cgh.2013.01.005_fr29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0168-8278(99)80010-5","article-title":"The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo","volume":"30","author":"Hellerbrand","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/jhep.2001.25349","article-title":"The role of Smad3 in mediating mouse hepatic stellate cell activation","volume":"34","author":"Schnabl","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr31","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1053\/jhep.2000.20243","article-title":"Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference","volume":"32","author":"Friedman","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1172\/JCI118055","article-title":"Cell-specific expression of transforming growth factor-beta in rat liver","volume":"96","author":"Bissell","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr33","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/jhep.2002.32673","article-title":"Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy","volume":"35","author":"Yata","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr34","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2353\/ajpath.2008.071121","article-title":"Divergent transforming growth factor-beta signaling in hepatic stellate cells after liver injury: functional effects on ECE-1 regulation","volume":"173","author":"Khimji","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cgh.2013.01.005_fr35","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2741\/4067","article-title":"Regulation of hepatic stellate cells by connective tissue growth factor","volume":"17","author":"Huang","year":"2012","journal-title":"Front Biosci"},{"key":"10.1016\/j.cgh.2013.01.005_fr36","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/hep.23102","article-title":"Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes","volume":"50","author":"Tong","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jcb.10494","article-title":"Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells","volume":"89","author":"Saxena","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.cgh.2013.01.005_fr38","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1172\/JCI18212","article-title":"NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis","volume":"112","author":"Bataller","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr39","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hep.20665","article-title":"Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats","volume":"41","author":"Bataller","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/jhep.2003.50044","article-title":"Vascular mediators in the injured liver","volume":"37","author":"Rockey","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr41","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/gut.2003.026658","article-title":"Hepatic fibrogenesis requires sympathetic neurotransmitters","volume":"53","author":"Oben","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2013.01.005_fr42","first-page":"660","article-title":"Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis","volume":"42","author":"Rockey","year":"1994","journal-title":"J Investig Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr43","first-page":"890","article-title":"Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice","volume":"38","author":"Inagaki","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr44","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1053\/j.gastro.2003.08.029","article-title":"Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin","volume":"125","author":"Kamada","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.01.005_fr45","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/5593","article-title":"Hepatocyte growth factor gene therapy of liver cirrhosis in rats","volume":"5","author":"Ueki","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr46","doi-asserted-by":"crossref","first-page":"25318","DOI":"10.1074\/jbc.M102630200","article-title":"Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells","volume":"276","author":"Kawada","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cgh.2013.01.005_fr47","doi-asserted-by":"crossref","first-page":"10756","DOI":"10.1016\/S0021-9258(18)81686-6","article-title":"Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix","volume":"264","author":"Friedman","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cgh.2013.01.005_fr48","doi-asserted-by":"crossref","first-page":"776A","DOI":"10.1016\/S0270-9139(03)81319-8","article-title":"Matrix compliance determines hepatic stellate cell phenotype","volume":"38","author":"Gaca","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr49","doi-asserted-by":"crossref","first-page":"G110","DOI":"10.1152\/ajpgi.00412.2010","article-title":"Hepatic stellate cells require a stiff environment for myofibroblastic differentiation","volume":"301","author":"Olsen","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2013.01.005_fr50","doi-asserted-by":"crossref","first-page":"30911","DOI":"10.1074\/jbc.272.49.30911","article-title":"The role of alpha1beta1 integrin in wound contraction","volume":"272","author":"Racine-Samson","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cgh.2013.01.005_fr51","doi-asserted-by":"crossref","first-page":"24863","DOI":"10.1074\/jbc.M513544200","article-title":"The role of integrin-linked kinase in liver wound healing","volume":"281","author":"Shafiei","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cgh.2013.01.005_fr52","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/labinvest.2011.155","article-title":"The function of integrin-linked kinase in normal and activated stellate cells: implications for fibrogenesis in wound healing","volume":"92","author":"Shafiei","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr53","doi-asserted-by":"crossref","first-page":"G245","DOI":"10.1152\/ajpgi.2000.279.2.G245","article-title":"Fibrogenesis II","volume":"279","author":"Arthur","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2013.01.005_fr54","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1074\/jbc.M310999200","article-title":"Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen","volume":"279","author":"Han","year":"2004","journal-title":"J Biol Chem"},{"issue":"Suppl 3","key":"10.1016\/j.cgh.2013.01.005_fr55","first-page":"S88","article-title":"Matrix metalloproteinases, the pros and cons, in liver fibrosis","volume":"21","author":"Han","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.gt.3301647","article-title":"Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors","volume":"9","author":"Garcia-Ba\u00f1uelos","year":"2002","journal-title":"Gene Ther"},{"key":"10.1016\/j.cgh.2013.01.005_fr57","first-page":"492A","article-title":"Regulation of smooth muscle myosin heavy chain isoforms in hepatic myofibroblasts during liver injury","volume":"30","author":"Xu","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr58","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1172\/JCI115905","article-title":"Fat-storing cells as liver-specific pericytes","volume":"90","author":"Pinzani","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr59","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI116769","article-title":"Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo","volume":"92","author":"Rockey","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr60","doi-asserted-by":"crossref","first-page":"G1010","DOI":"10.1152\/ajpgi.00350.2010","article-title":"Increased contractility of hepatic stellate cells in cirrhosis is mediated by enhanced Ca2+-dependent and Ca2+-sensitization pathways","volume":"300","author":"Iizuka","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2013.01.005_fr61","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/labinvest.2012.113","article-title":"Salvianolic acid B lowers portal pressure in cirrhotic rats and attenuates contraction of rat hepatic stellate cells by inhibiting RhoA signaling pathway","volume":"92","author":"Xu","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr62","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.23222","article-title":"Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis","volume":"50","author":"Trebicka","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr63","first-page":"176","article-title":"Inhibitory effects of prostaglandin E1 on activation of hepatic stellate cells in rabbits with schistosomiasis","volume":"6","author":"Zou","year":"2007","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.cgh.2013.01.005_fr64","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/jpet.111.179143","article-title":"Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice","volume":"337","author":"van Beuge","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2013.01.005_fr65","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1007\/s10620-012-2183-7","article-title":"Adenine induces differentiation of rat hepatic stellate cells","volume":"57","author":"Watanabe","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2013.01.005_fr66","doi-asserted-by":"crossref","first-page":"e13955","DOI":"10.1371\/journal.pone.0013955","article-title":"Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand","volume":"5","author":"Li","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2013.01.005_fr67","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1053\/gast.2001.27188","article-title":"Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats","volume":"121","author":"Wright","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.01.005_fr68","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/01.LAB.0000069036.63405.5C","article-title":"Apoptotic body engulfment by a human stellate cell line is profibrogenic","volume":"83","author":"Canbay","year":"2003","journal-title":"Lab Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr69","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","article-title":"Senescence of activated stellate cells limits liver fibrosis","volume":"134","author":"Krizhanovsky","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.cgh.2013.01.005_fr70","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.22351","article-title":"Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence","volume":"48","author":"Deleve","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr71","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4161\/auto.8.1.18105","article-title":"Autophagy: a new player in hepatic stellate cell activation","volume":"8","author":"Thoen","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.cgh.2013.01.005_fr72","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jhep.2011.07.010","article-title":"A role for autophagy during hepatic stellate cell activation","volume":"55","author":"Thoen","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr73","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4161\/auto.19947","article-title":"Autophagy fuels tissue fibrogenesis","volume":"8","author":"Her\u0144ndez-Gea","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.cgh.2013.01.005_fr74","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJM199202203260802","article-title":"A randomized trial of prednisolone in patients with severe alcoholic hepatitis","volume":"326","author":"Ramond","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr75","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0168-8278(01)00190-8","article-title":"Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood","volume":"35","author":"Spahr","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr76","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/imj.1970.19.1.54","article-title":"Reversal of \u201ccirrhosis\u201d in idiopathic haemochromatosis following long-term intensive venesection therapy","volume":"19","author":"Powell","year":"1970","journal-title":"Australas Ann Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr77","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/0016-5085(88)90379-4","article-title":"Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis","volume":"95","author":"Blumberg","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.01.005_fr78","first-page":"1008","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr79","first-page":"109","article-title":"Effects of colchicine and colchiceine in a biochemical model of liver injury and fibrosis","volume":"29","author":"Rodr\u00edguez","year":"1998","journal-title":"Arch Med Res"},{"key":"10.1016\/j.cgh.2013.01.005_fr80","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM198612043152304","article-title":"A prospective trial of colchicine for primary biliary cirrhosis","volume":"315","author":"Kaplan","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr81","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJM198806303182602","article-title":"Colchicine in the treatment of cirrhosis of the liver","volume":"318","author":"Kershenobich","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr82","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1034\/j.1600-0676.2001.021002129.x","article-title":"Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis","volume":"21","author":"Rambaldi","year":"2001","journal-title":"Liver"},{"key":"10.1016\/j.cgh.2013.01.005_fr83","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1053\/j.gastro.2005.01.057","article-title":"Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival","volume":"128","author":"Morgan","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.01.005_fr84","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.1840160325","article-title":"Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma","volume":"16","author":"Rockey","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr85","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2893.2005.00689.x","article-title":"Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection","volume":"13","author":"Muir","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cgh.2013.01.005_fr86","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cld.2008.07.011","article-title":"Current and future anti-fibrotic therapies for chronic liver disease","volume":"12","author":"Rockey","year":"2008","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2013.01.005_fr87","doi-asserted-by":"crossref","first-page":"35715","DOI":"10.1074\/jbc.M006577200","article-title":"Peroxisome proliferator-activated receptors and hepatic stellate cell activation","volume":"275","author":"Miyahara","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cgh.2013.01.005_fr88","doi-asserted-by":"crossref","first-page":"11392","DOI":"10.1074\/jbc.M310284200","article-title":"Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells","volume":"279","author":"Hazra","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cgh.2013.01.005_fr89","doi-asserted-by":"crossref","first-page":"G902","DOI":"10.1152\/ajpgi.00124.2006","article-title":"Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis","volume":"291","author":"Yang","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2013.01.005_fr90","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.ajpath.2011.02.035","article-title":"Adiponectin regulation of stellate cell activation via PPAR\u03b3-dependent and -independent mechanisms","volume":"178","author":"Shafiei","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cgh.2013.01.005_fr91","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00011-010-0226-0","article-title":"Effectiveness of the PPAR\u03b3 agonist, GW570, in liver fibrosis","volume":"59","author":"Yang","year":"2010","journal-title":"Inflamm Res"},{"key":"10.1016\/j.cgh.2013.01.005_fr92","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.12.003","article-title":"Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection","volume":"138","author":"McHutchison","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.01.005_fr93","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1097\/01.ALC.0000093743.03049.80","article-title":"Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease","volume":"27","author":"Lieber","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.cgh.2013.01.005_fr94","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/hep.510260316","article-title":"Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats","volume":"26","author":"Boigk","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr95","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0168-8278(01)00148-9","article-title":"Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1","volume":"35","author":"Jia","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr96","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00004836-200310000-00013","article-title":"Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons","volume":"37","author":"Lieber","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2013.01.005_fr97","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0168-8278(89)90083-4","article-title":"Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver","volume":"9","author":"Ferenci","year":"1989","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr98","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0168-8278(98)80285-7","article-title":"Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial","volume":"28","author":"Par\u00e9s","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr99","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2362.1997.910615.x","article-title":"Effect of colchiceine and ursodeoxycholic acid on hepatocyte and erythrocyte membranes and liver histology in experimentally induced carbon tetrachloride cirrhosis in rats","volume":"27","author":"Nava-Ocampo","year":"1997","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","article-title":"Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis","volume":"39","author":"Poupon","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr101","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr102","first-page":"G116","article-title":"Effect of vitamin E supplementation on hepatic fibrogenesis in chronic dietary iron overload","volume":"272","author":"Brown","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cgh.2013.01.005_fr103","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1053\/gast.1997.v113.pm9322499","article-title":"A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C","volume":"113","author":"Houglum","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.01.005_fr104","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0168-8278(03)00476-8","article-title":"A randomized placebo controlled trial of vitamin E for alcoholic hepatitis","volume":"40","author":"Mezey","year":"2004","journal-title":"J Hepatol"},{"issue":"Suppl","key":"10.1016\/j.cgh.2013.01.005_fr105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0168-8278(02)80041-1","article-title":"A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis","volume":"36","author":"Stewart","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr106","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr107","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S0168-8278(03)00094-1","article-title":"Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet","volume":"38","author":"Sakaida","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr108","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hep.510290108","article-title":"Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats","volume":"29","author":"Shimizu","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr109","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3748\/wjg.v8.i3.515","article-title":"Salvia miltiorrhiza monomer IH764-3 induces hepatic stellate cell apoptosis via caspase-3 activation","volume":"8","author":"Zhang","year":"2002","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2013.01.005_fr110","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.3748\/wjg.v11.i42.6638","article-title":"He Jie Tang in the treatment of chronic hepatitis B patients","volume":"11","author":"Chen","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"Suppl","key":"10.1016\/j.cgh.2013.01.005_fr111","first-page":"E67","article-title":"Treatment of chronic liver diseases with traditional Chinese medicine","volume":"15","author":"Wang","year":"2000","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr112","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-2002-30104","article-title":"Herbal hepatotoxicity","volume":"22","author":"Stedman","year":"2002","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cgh.2013.01.005_fr113","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.01.005_fr114","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0168-8278(02)00230-1","article-title":"Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study","volume":"37","author":"Spahr","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr115","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0168-8278(02)00442-7","article-title":"Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis","volume":"38","author":"Tilg","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr116","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1572-0241.2004.04034.x","article-title":"A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis","volume":"99","author":"Menon","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2013.01.005_fr117","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr118","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","article-title":"A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis","volume":"135","author":"Boetticher","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.01.005_fr119","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10565-007-9039-5","article-title":"Pentoxifylline downregulates alpha (I) collagen expression by the inhibition of IkappaBalpha degradation in liver stellate cells","volume":"24","author":"Hern\u00e1ndez","year":"2008","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.cgh.2013.01.005_fr120","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1600-0463.2011.02868.x","article-title":"Pentoxifylline inhibits hepatic stellate cells proliferation via the Raf\/ERK pathway","volume":"120","author":"Zhang","year":"2012","journal-title":"APMIS"},{"key":"10.1016\/j.cgh.2013.01.005_fr121","first-page":"20","article-title":"Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial","volume":"60","author":"Sidhu","year":"2012","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.cgh.2013.01.005_fr122","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0232-1513(11)80156-8","article-title":"The effect of d-penicillamine on CCl4-induced experimental liver cirrhosis","volume":"43","author":"Schaff","year":"1991","journal-title":"Exp Pathol"},{"key":"10.1016\/j.cgh.2013.01.005_fr123","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0741-8329(02)00226-4","article-title":"Role of abnormal methionine metabolism in alcoholic liver injury","volume":"27","author":"Lu","year":"2002","journal-title":"Alcohol"},{"key":"10.1016\/j.cgh.2013.01.005_fr124","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2036.2004.01819.x","article-title":"Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?","volume":"19","author":"Aithal","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2013.01.005_fr125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0168-8278(05)80043-1","article-title":"The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European Multicentre Study Group","volume":"17","year":"1993","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr126","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/hep.1840050613","article-title":"A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis","volume":"5","author":"Bodenheimer","year":"1985","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr127","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM198504183121602","article-title":"Trial of penicillamine in advanced primary biliary cirrhosis","volume":"312","author":"Dickson","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr128","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/0003-4819-126-9-199705010-00002","article-title":"Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment","volume":"126","author":"Kaplan","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr129","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/gast.1999.0029900400","article-title":"Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial","volume":"117","author":"Hendrickse","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.01.005_fr130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1572-0241.2003.07173.x","article-title":"Methotrexate therapy for primary biliary cirrhosis","volume":"98","author":"Bach","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2013.01.005_fr131","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/hep.20103","article-title":"A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results","volume":"39","author":"Kaplan","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr132","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0168-8278(99)80263-3","article-title":"S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial","volume":"30","author":"Mato","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr133","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1034\/j.1600-0676.2001.210606.x","article-title":"Meta-analysis of propylthiouracil for alcoholic liver disease\u2013a Cochrane Hepato-Biliary Group Review","volume":"21","author":"Rambaldi","year":"2001","journal-title":"Liver"},{"key":"10.1016\/j.cgh.2013.01.005_fr134","first-page":"217","article-title":"Delivering silence: advancements in developing siRNA therapeutics","volume":"11","author":"Novobrantseva","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.cgh.2013.01.005_fr135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1758-907X-1-14","article-title":"A status report on RNAi therapeutics","volume":"1","author":"Vaishnaw","year":"2010","journal-title":"Silence"},{"key":"10.1016\/j.cgh.2013.01.005_fr136","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/labinvest.2011.86","article-title":"A polymeric nanoparticle formulation of curcumin (NanoCurc\u2122) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation","volume":"91","author":"Bisht","year":"2011","journal-title":"Lab Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr137","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nm0496-418","article-title":"Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney","volume":"2","author":"Isaka","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr138","doi-asserted-by":"crossref","first-page":"12719","DOI":"10.1073\/pnas.96.22.12719","article-title":"In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis","volume":"96","author":"George","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cgh.2013.01.005_fr139","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1124\/jpet.106.114496","article-title":"Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells","volume":"321","author":"Gonzalo","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2013.01.005_fr140","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1113\/jphysiol.2011.219691","article-title":"Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut","volume":"590","author":"Seki","year":"2012","journal-title":"J Physiol"},{"key":"10.1016\/j.cgh.2013.01.005_fr141","doi-asserted-by":"crossref","first-page":"e23037","DOI":"10.1371\/journal.pone.0023037","article-title":"Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis","volume":"6","author":"G\u00f3mez-Hurtado","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2013.01.005_fr142","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","article-title":"Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4","volume":"21","author":"Dapito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cgh.2013.01.005_fr143","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr144","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jhep.2012.01.019","article-title":"Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease","volume":"56","author":"Fouts","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr145","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/j.1742-4658.2010.07632.x","article-title":"MicroRNAs and the regulation of fibrosis","volume":"277","author":"Jiang","year":"2010","journal-title":"FEBS J"},{"key":"10.1016\/j.cgh.2013.01.005_fr146","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbrc.2011.07.041","article-title":"Suppression of hepatic stellate cell activation by microRNA-29b","volume":"412","author":"Sekiya","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cgh.2013.01.005_fr147","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/hep.25613","article-title":"Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis","volume":"56","author":"Lakner","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr148","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Barry-Hamilton","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr149","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1152\/ajpheart.00335.2010","article-title":"Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects","volume":"299","author":"L\u00f3pez","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cgh.2013.01.005_fr150","doi-asserted-by":"crossref","first-page":"136ra71","DOI":"10.1126\/scitranslmed.3003421","article-title":"A peptide derived from endostatin ameliorates organ fibrosis","volume":"4","author":"Yamaguchi","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr151","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/labinvest.2008.75","article-title":"The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis","volume":"88","author":"Xu","year":"2008","journal-title":"Lab Invest"},{"key":"10.1016\/j.cgh.2013.01.005_fr152","doi-asserted-by":"crossref","first-page":"348","DOI":"10.5483\/BMBRep.2012.45.6.276","article-title":"Anti-fibrotic effects of L-2-oxothiazolidine-4-carboxylic acid via modulation of nuclear factor erythroid 2-related factor 2 in rats","volume":"45","author":"Kim","year":"2012","journal-title":"BMB Rep"},{"key":"10.1016\/j.cgh.2013.01.005_fr153","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1440-1681.2009.05194.x","article-title":"Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells","volume":"36","author":"Zhao","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cgh.2013.01.005_fr154","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1096\/fj.02-1157fje","article-title":"Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis","volume":"17","author":"Titos","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.cgh.2013.01.005_fr155","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr156","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0168-8278(98)80318-8","article-title":"Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores","volume":"28","author":"Pilette","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr157","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1309\/D7AU-EYW7-4B6C-K08Y","article-title":"An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C","volume":"114","author":"O'Brien","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cgh.2013.01.005_fr158","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr159","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection","volume":"97","author":"Regev","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2013.01.005_fr160","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1002\/hep.21046","article-title":"Noninvasive measures of liver fibrosis","volume":"43","author":"Rockey","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr161","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1148\/radiol.2272020193","article-title":"Severe liver fibrosis or cirrhosis: accuracy of US for detection\u2013analysis of 300 cases","volume":"227","author":"Colli","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.cgh.2013.01.005_fr162","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0140-6736(00)04258-6","article-title":"Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study","volume":"357","author":"Imbert-Bismut","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2013.01.005_fr163","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr164","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nm1006","article-title":"Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics","volume":"10","author":"Callewaert","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2013.01.005_fr165","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2005.10.019","article-title":"Performance of serum marker panels for liver fibrosis in chronic hepatitis C","volume":"44","author":"Parkes","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr166","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/hep.22517","article-title":"Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay","volume":"48","author":"Mayo","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr167","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/gut.2009.203166","article-title":"Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease","volume":"59","author":"Parkes","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2013.01.005_fr168","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24467","article-title":"Molecular imaging of hepatic stellate cell activity by visualization of hepatic integrin \u03b1v\u03b23 expression with SPECT in rat","volume":"54","author":"Li","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.01.005_fr169","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s00330-010-1988-z","article-title":"MR imaging of activated hepatic stellate cells in liver injured by CCl4 of rats with integrin-targeted ultrasmall superparamagnetic iron oxide","volume":"21","author":"Wang","year":"2011","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cgh.2013.01.005_fr170","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1124\/jpet.107.132290","article-title":"Cellular targeting of the apoptosis-inducing compound gliotoxin to fibrotic rat livers","volume":"324","author":"Hagens","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2013.01.005_fr171","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1016\/j.biomaterials.2011.03.044","article-title":"Target specific systemic delivery of TGF-\u03b2 siRNA\/(PEI-SS)-g-HA complex for the treatment of liver cirrhosis","volume":"32","author":"Park","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.cgh.2013.01.005_fr172","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jhep.2011.04.008","article-title":"Targeted therapy of liver fibrosis\/cirrhosis and its complications","volume":"55","author":"Poelstra","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2013.01.005_fr173","doi-asserted-by":"crossref","first-page":"265101","DOI":"10.1088\/0957-4484\/23\/26\/265101","article-title":"The improving effects on hepatic fibrosis of interferon-\u03b3 liposomes targeted to hepatic stellate cells","volume":"23","author":"Li","year":"2012","journal-title":"Nanotechnology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356513000062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356513000062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:11:06Z","timestamp":1761541866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356513000062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":178,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1542356513000062"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2013.01.005","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translating an Understanding of the Pathogenesis of Hepatic Fibrosis to Novel Therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2013.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}